monoethylglycinexylidide has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Waller, ES | 1 |
| Arvela, P; Bäckstrom, M; Pelkonen, O; Rautio, A; Sotaniemi, EA | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Davoll, S; Debuire, B; Lemoine, A; Pham, P; Salvucci, M | 1 |
1 trial(s) available for monoethylglycinexylidide and Kidney Diseases
| Article | Year |
|---|---|
Acute cyclosporine toxicity after liver transplantation is predicted by the lidocaine monoethylglycinexylidide test in the donor.
Topics: Adolescent; Adult; Aged; Cyclosporine; Female; Humans; Kidney Diseases; Lidocaine; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Nervous System Diseases; Prognosis; Prospective Studies; Tissue Donors | 1997 |
2 other study(ies) available for monoethylglycinexylidide and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetic principles of lidocaine dosing in relation to disease state.
Topics: Adult; Age Factors; Aged; Animals; Dogs; Drug Therapy, Combination; Half-Life; Heart Failure; Humans; Kidney Diseases; Kinetics; Lidocaine; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Time Factors | 1981 |
CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.
Topics: Administration, Oral; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Capsules; Coumarins; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Epilepsy; Female; Humans; Injections, Intravenous; Isoenzymes; Kidney Diseases; Kidney Function Tests; Lidocaine; Liver; Liver Diseases, Alcoholic; Liver Function Tests; Male; Middle Aged; Mixed Function Oxygenases; Peptide Fragments; Procollagen; Umbelliferones | 1995 |